Photo taken from Elisa Agostinetto/LinkedIn
Jan 28, 2024, 18:29
Elisa Agostinetto: Estradiol levels remain the biomarker of choice
Elisa Agostinetto, Clinical Research Fellow at the Institute Jules Bordet, recently shared on X/Twitter:
“Out in npj Journals Breast a nice review on the selection of appropriate biomarkers to monitor the effectiveness of ovarian function suppression with GnRH agonists in ER+.
Estradiol levels remain the biomarker of choice.”
Source: Elisa Agostinetto/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 20, 2024, 17:31
Dec 20, 2024, 17:31
Dec 20, 2024, 17:22
Dec 20, 2024, 17:18
Dec 20, 2024, 17:05
Dec 20, 2024, 16:47